PRTA Prothena Corp Public Ltd Co
Price (delayed)
$9.2
Market cap
$495.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.27
Enterprise value
$34.66M
Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating
Highlights
The company's gross profit rose by 48% YoY
Prothena's revenue has increased by 48% YoY
The company's equity fell by 13% YoY and by 9% QoQ
The quick ratio has declined by 13% since the previous quarter and by 12% year-on-year
Key stats
What are the main financial stats of PRTA
Market
Valuations
Earnings
Shares outstanding
53.83M
Market cap
$495.21M
Enterprise value
$34.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
3.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.26
Revenue
$135.16M
Gross profit
$135.16M
Operating income
-$154.56M
Net income
-$122.31M
EBIT
-$128.93M
EBITDA
-$125.35M
Free cash flow
-$150.35M
Per share
Balance sheet
Liquidity
EPS
-$2.27
EPS diluted
-$2.27
Free cash flow per share
-$2.8
Book value per share
$9.05
Revenue per share
$2.51
TBVPS
$10.17
Total assets
$547.11M
Total liabilities
$60.18M
Debt
$10.84M
Equity
$486.93M
Working capital
$436.91M
Debt to equity
0.02
Current ratio
10.01
Quick ratio
9.72
Net debt/EBITDA
3.67
Margins
Efficiency
Dividend
EBITDA margin
-92.7%
Gross margin
100%
Net margin
-90.5%
Operating margin
-114.4%
Return on assets
-20.3%
Return on equity
-23.2%
Return on invested capital
-302.5%
Return on capital employed
-25.9%
Return on sales
-95.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRTA stock price
How has the Prothena stock price performed over time
Intraday
-0.65%
1 week
-5.06%
1 month
-33.04%
1 year
-56.19%
YTD
-33.57%
QTD
-25.66%
Financial performance
How have Prothena's revenue and profit performed over time
Revenue
$135.16M
Gross profit
$135.16M
Operating income
-$154.56M
Net income
-$122.31M
Gross margin
100%
Net margin
-90.5%
The company's gross profit rose by 48% YoY
Prothena's revenue has increased by 48% YoY
The operating margin is up by 45% year-on-year and by 9% since the previous quarter
Prothena's net margin has increased by 44% YoY and by 8% from the previous quarter
Growth
What is Prothena's growth rate over time
Valuation
What is Prothena stock price valuation
P/E
N/A
P/B
1.02
P/S
3.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.26
The company's EPS rose by 18% YoY and by 8% QoQ
PRTA's price to book (P/B) is 74% lower than its 5-year quarterly average of 3.9 and 46% lower than its last 4 quarters average of 1.9
The company's equity fell by 13% YoY and by 9% QoQ
PRTA's price to sales (P/S) is 98% lower than its 5-year quarterly average of 191.9 and 55% lower than its last 4 quarters average of 8.1
Prothena's revenue has increased by 48% YoY
Efficiency
How efficient is Prothena business performance
The ROIC has soared by 69% YoY and by 12% from the previous quarter
The company's return on sales rose by 46% YoY and by 9% QoQ
The ROE has increased by 6% YoY and by 4.1% from the previous quarter
Dividends
What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRTA.
Financial health
How did Prothena financials performed over time
The total liabilities has dropped by 55% year-on-year
The total assets has decreased by 21% YoY and by 8% from the previous quarter
Prothena's debt is 98% less than its equity
The company's equity fell by 13% YoY and by 9% QoQ
Prothena's debt has decreased by 8% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.